Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
Why now
Thesis: Australian patent extends breast cancer vaccine IP through 2040
Catalyst to watch: Further patent grants or trial progress
Main risk: Small company, unlisted in slug set
Why it matters
An Australian composition-of-matter patent extends IP protection for a breast cancer vaccine, but the company is small and unlisted in the allowed slug set.
Details
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estate Continues expansion of global intellectual property coverage in markets with increasing breast cancer incidence rates SAN...
Sources
- prnewswire · 2026-09-21 12:45 UTC